Arvinas Androgen Receptor, Inc.
Clinical trials sponsored by Arvinas Androgen Receptor, Inc., explained in plain language.
Now part of
Arvinas, Inc.
ARVN
NASDAQ
Biotech developing PROTAC protein degraders, including for prostate cancer.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.